PKC ν Activators
PKC ν Activators consist of a collection of compounds that indirectly enhance the activity of PKC ν, a protein kinase involved in a variety of cellular signaling pathways. These activators primarily function by modulating the activity of other protein kinase C (PKC) isoforms or kinases, potentially leading to a compensatory increase in PKC ν signaling. Bryostatin 1 and PMA are notable examples, as they activate conventional PKC isoforms, which may result in enhanced PKC ν activity due to interconnected signaling pathways within the PKC family. Broad-spectrum PKC inhibitors like Gö 6983, Balanol, Ro 31-8220, and Chelerythrine chloride also contribute to this process by inhibiting several PKC isoforms, potentially shifting the balance of cellular signaling towards PKC ν. This compensatory mechanism highlights PKC ν's adaptability and its potential to maintain signaling homeostasis under varying cellular conditions.
Moreover, specific kinase inhibitors such as Staurosporine, Enzastaurin, Sotrastaurin, Ruboxistaurin, PKC-412, and Bisindolylmaleimide I (GF 109203X) play a significant role in modulating PKC ν activity. For instance, Staurosporine's broad-spectrum kinase inhibition and Enzastaurin's targeted inhibition of PKC β may lead to increased reliance on PKC ν for certain signaling functions. Similarly, Sotrastaurin and Ruboxistaurin, by targeting multiple PKC isoforms, including PKC β, may enhance PKC ν's role in specific cellular responses. PKC-412's multi-kinase targeting and Bisindolylmaleimide I (GF 109203X)'s inhibition of PKC isoforms also suggest a potential increase in PKC ν signaling in response to altered kinase activity. Collectively, these PKC ν Activators underscore the complex regulation of PKC ν in cellular signaling processes, emphasizing its importance in maintaining signaling integrity and cellular homeostasis. The diversity of these activators reflects the intricate network of signaling pathways in which PKC ν is involved and its capacity to adapt and compensate for alterations in cellular kinase activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $245.00 | 9 | |
Bryostatin 1, a PKC modulator, indirectly enhances PKC ν activity by activating conventional PKC isoforms, potentially leading to compensatory mechanisms that increase PKC ν signaling in specific pathways. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA, a potent PKC activator, indirectly activates PKC ν by stimulating PKC isoforms, which may result in increased PKC ν activity due to cross-talk within PKC family signaling pathways. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Gö 6983, a broad-spectrum PKC inhibitor, indirectly enhances PKC ν activity by inhibiting other PKC isoforms, potentially leading to a compensatory increase in PKC ν-mediated signaling. | ||||||
Balanol | 63590-19-2 | sc-503251 | 10 mg | $13500.00 | ||
Balanol, a PKC inhibitor, indirectly activates PKC ν by inhibiting certain PKC isoforms, potentially shifting signaling reliance to PKC ν in various cellular processes. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro 31-8220, a PKC inhibitor, indirectly enhances PKC ν activity by targeting other PKC isoforms, which may result in an increased role for PKC ν in specific signaling pathways. | ||||||
Enzastaurin | 170364-57-5 | sc-364488 sc-364488A sc-364488B | 10 mg 50 mg 200 mg | $259.00 $612.00 $1721.00 | 3 | |
Enzastaurin, a PKC β inhibitor, indirectly enhances PKC ν activity by specifically targeting PKC β, which may lead to compensatory PKC ν signaling in certain pathways. | ||||||
Ruboxistaurin | 169939-94-0 | sc-507364 | 25 mg | $1080.00 | ||
Ruboxistaurin, a PKC β inhibitor, indirectly enhances PKC ν activity by inhibiting PKC β, potentially leading to an increase in PKC ν signaling in response to cellular stimuli. | ||||||
Chelerythrine chloride | 3895-92-9 | sc-3547 sc-3547A | 5 mg 25 mg | $90.00 $317.00 | 17 | |
Chelerythrine chloride, a PKC inhibitor, indirectly activates PKC ν by inhibiting various PKC isoforms, potentially increasing the reliance on PKC ν for certain signaling functions. | ||||||
PKC-412 | 120685-11-2 | sc-200691 sc-200691A | 1 mg 5 mg | $52.00 $114.00 | 10 | |
PKC-412, a multi-kinase inhibitor, indirectly enhances PKC ν activity by targeting a range of kinases, potentially leading to compensatory PKC ν signaling. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide I (GF 109203X), a PKC inhibitor, indirectly activates PKC ν by inhibiting other PKC isoforms, potentially leading to increased PKC ν activity in specific signaling pathways. | ||||||